If you have trouble affording prescription drugs, some independent pharmacists say that so-called pharmacy middlemen are ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

ANSWER: In general, I recommend against stopping prescription medications without your doctor telling you to, and I hope to ...

Dear F.W.: In general, I recommend against stopping prescription medications without your doctor telling you to, and I hope ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

Anemia drug Reblozyl generated $447 million in third ... Legacy Portfolio revenues were primarily driven by higher demand for Eliquis, partially offset by a decline in demand for Sprycel due ...

However, Pfizer’s non-COVID operational revenues improved in the first half of 2024, driven by its key in-line products like Prevnar, Vyndaqel and Eliquis, new launches like Abrysvo, Velsipity ...